Special report from CEVR researchers in Expert Review of Pharmacoeconomics and Outcomes Research: "The lag from FDA approval to published cost-utility evidence."
New paper by CEVR researchers in the journal Blood: “Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.”
Briefing Dr. James Chambers will speak on February 5th at the Health Affairs Briefing in DC: Biomedical Innovation. Follow us on Twitter for updates and join in with #HA_BiomedInnovation.
Cost-effectiveness analysis "Benefits, Harms, and Cost-Effectiveness of Supplemental Ultrasonography Screening for Women With Dense Breasts" in the New England Journal of Medicine
New paper by CEVR researchers in Health Affairs: Medicare is scrutinizing evidence more tightly for national coverage determinations